Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KT-579 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| KT-579 | ACTIVE_COMPARATOR | Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-579. |
| Placebo | PLACEBO_COMPARATOR | Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo. |
| Name | Type | Description |
|---|---|---|
| KT-579 | DRUG | Oral drug |
| Placebo | DRUG | Oral drug |
Inclusion Criteria: * Participants with a weight of at least 50 kg if male or 40 kg if female, and a body mass index (BMI) between 18.0 and 32.0 kg/m² (inclusive) at Screening. * Participants must be willing and able to read, understand, and sign an informed consent form (ICF) which includes compli...
KT-579 is an investigational oral small molecule being developed by Kymera Therapeutics, Inc. It is in Phase 1 clinical development and is currently being studied in healthy adult participants. KT-579 is designed to target IRF5, a protein involved in immune signaling. No approved indication has been established for KT-579.
KT-579 targets IRF5, also known as interferon regulatory factor 5. IRF5 is a transcription factor involved in immune and inflammatory signaling pathways. By targeting IRF5, KT-579 is designed to modulate this pathway. The drug is an orally administered small molecule.
KT-579 is being developed by Kymera Therapeutics, Inc., which trades on the Nasdaq under the ticker symbol KYMR. Kymera Therapeutics is a biopharmaceutical company focused on targeted protein degradation. The company is the sponsor of the ongoing clinical trial for KT-579.
KT-579 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is a first-in-human study evaluating orally administered KT-579 in healthy adult participants.
KT-579 is being evaluated in one active clinical trial, NCT07412288, titled "First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants." The trial is currently recruiting and is expected to enroll 96 participants. It is a randomized, double-blind, placebo-controlled Phase 1 study conducted in the United States.